• WedgeGlobal creative consolidation to WPP (2019) — Lilly named WPP its strategic creative + production partner globally. CORE WPP RELATIONSHIP. Renewed since.
• WhyDiabetes/Obesity direct competitor: Novo Nordisk (Ozempic, Wegovy — semaglutide platform; #1 global pharma by mcap before Lilly overtook 2024). This is the highest-stakes pharma rivalry in the world right now. Novo Taiwan = Lilly Taiwan's direct competitor in TW. CDK4/6 oncology: Novartis (Kisqali), Pfizer (Ibrance). Psoriasis: Novartis (Cosentyx — predecessor in class), AbbVie (Skyrizi), J&J (Tremfya, Stelara). CGRP migraine: Pfizer (Vydura/Nurtec), Lundbeck (Vyepti), Teva (Ajovy), AbbVie (Qulipta). Alzheimer's (forthcoming category): Biogen/Eisai (Leqembi).

1. W1Global creative consolidation to WPP (2019) — Lilly named WPP its strategic creative + production partner globally. CORE WPP RELATIONSHIP. Renewed since.
2. W2Specifically: VML (formed 2024 from VMLY&R + Wunderman Thompson merger) holds Lilly creative; Hogarth holds Lilly production; Ogilvy Health holds some Lilly Rx brands. All WPP.
3. W3Lilly is one of WPP's flagship global pharma wins post-2019 — comparable strategic weight to AZ on the media side
4. W4Mounjaro/Zepbound is the single biggest pharma launch globally — Taiwan rollout creates large brand investment wave
5. W5Kisunla (Alzheimer's) — first major TW Alzheimer's launch potential — category-defining moment
6. W6Lilly increasing global marketing spend faster than peers (US$117B revenue trajectory 2024 → 2030)

• Diabetes/Obesity direct competitor: Novo Nordisk (Ozempic, Wegovy — semaglutide platform; #1 global pharma by mcap before Lilly overtook 2024). This is the highest-stakes pharma rivalry in the world right now. Novo Taiwan = Lilly Taiwan's direct competitor in TW. CDK4/6 oncology: Novartis (Kisqali), Pfizer (Ibrance). Psoriasis: Novartis (Cosentyx — predecessor in class), AbbVie (Skyrizi), J&J (Tremfya, Stelara). CGRP migraine: Pfizer (Vydura/Nurtec), Lundbeck (Vyepti), Teva (Ajovy), AbbVie (Qulipta). Alzheimer's (forthcoming category): Biogen/Eisai (Leqembi).
• VERY HIGH (CORE INCUMBENT). Lilly named WPP its global creative + production partner in 2019 — one of WPP's most strategic pharma wins. VML (post-2024 merger), Ogilvy Health, and Hogarth all hold significant Lilly scope. Lilly Taiwan creative work cascades through WPP Asia Pacific. WPP MEDIA: Lilly global media history more mixed — Mediahub (IPG) historical, with shifts; less clear-cut than creative. THIS IS A DEFEND-THE-INCUMBENT account for WPP Taiwan on creative — Jimmy Kuo's team has structural advantage. Pitch posture: defensive on creative (relationship-protection, scope-expansion into Mounjaro/Zepbound/Kisunla launches), offensive on media (less consolidated globally, project-level media wins viable in TW).
• Mounjaro Taiwan NHI reimbursement decisions (currently self-pay tier — NHI access expansion)
• Zepbound Taiwan TFDA approval status (obesity indication)
• Trulicity → Mounjaro switching campaigns (mature → next-gen GLP-1)
• Kisunla (donanemab) Taiwan TFDA submission / approval
• Lilly Taiwan GM changes (vendor review trigger)
• Global Lilly quarterly earnings — diabetes/obesity DTC spend disclosures
• Novo Nordisk Taiwan competitive moves (Ozempic/Wegovy positioning)

• General Manager — Eli Lilly Taiwan (incumbent unverified)GM Lilly Taiwan

  since

  GM rotates 3-5 years. Reports to Lilly Asia. LinkedIn/press diligence required to confirm current incumbent.

  Source ↗
• BU Lead — Diabetes & Obesity (HIGHEST PRIORITY)Diabetes & Obesity BU Lead — Lilly Taiwan

  since

  Highest budget pool. Mounjaro launch lead. Single most important agency-relationship target in Lilly TW.

  Source ↗
• BU Leads — Oncology, Immunology, NeuroscienceBU Lead — Lilly Taiwan

  since

  Therapy-area brand-team leads. Smaller budgets but high creative opportunity (Verzenio, Taltz, Ebglyss, Emgality launches).

  Source ↗

Eli Lilly Taiwan (台灣禮來) is mid-tier MNC pharma in Taiwan (top 8-10 by Rx revenue) but with disproportionate strategic momentum globally — Lilly is the WORLD'S MOST VALUABLE PHARMA COMPANY by market cap (>$700B at peak 2024) driven by GLP-1 / tirzepatide platform (Mounjaro / Zepbound). Taiwan portfolio is DOMINANT in diabetes (Trulicity established, Mounjaro launching), expanding in oncology (Verzenio breast cancer), immunology (Taltz vs Cosentyx/Skyrizi), and CGRP migraine (Emgality). Taiwan Rx DTC restricted (藥事法); HOWEVER diabetes is a category where unbranded disease-awareness can run at high consumer reach (T2D prevalence ~11% in TW adults — 2.3M+ patients). Obesity Rx (Zepbound) — if TFDA approves — would be a category-defining DTC moment globally Lilly has pushed limits in US DTC (Zepbound consumer ads); Taiwan TFDA would restrict more but unbranded weight-management awareness is feasible. Estimated NT$200-400M ad spend currently, with significant UPSIDE if Mounjaro/Zepbound consumer-awareness waves accelerate.

No campaigns surfaced in research.

No decision-makers identified.

Eli Lilly Taiwan reports into Lilly Asia (Shanghai + Singapore hubs). General Manager rotates 3-5 years. Commercial structure split by Business Unit: Diabetes & Obesity (largest, fastest-growing), Oncology, Immunology, Neuroscience. Lilly global commercial operations: Indianapolis HQ with strong central brand-team control.